pocketful logo
Syngene International Ltd logo

Syngene International Ltd

NSE: SYNGENE BSE: 539268

₹414.75

(1.69%)

Mon, 23 Mar 2026, 03:28 pm

mtf coin illustrationMTF 5x

Syngene International Share Price Live Chart

1 Day

0 (0%)

No Result Found

Summary

  • Market Cap

    16707.88

  • Net Profit

    496.20

  • P/B

    6.18

  • Sector P/E

    53.44

  • P/E

    58.89

  • EV/EBITDA

    25.33

  • Debt/Equity (Industry)

    0.40

  • Interest Cover (Industry)

    5.71

  • ROCE (Industry)

    12.15

  • RONW (Industry)

    11.95

  • ROE

    11.05

  • ROCE

    13.37

  • Debt/Equity

    0.13

  • EPS (TTM)

    10.16

  • Dividend Yield

    0.30

  • Book Value

    117.51

  • Interest Cover

    13.43

Analysis

all

thumbs up icon

Pros

  • Performance (ROE) is expected to be above the current IN Life Sciences industry average.
  • Syngene International's revenue growth is expected to exceed the India market average.
  • Syngene International is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Syngene International is profitable, therefore cash runway is not a concern.
  • Syngene International is profitable, therefore cash runway is not a concern.
thumbs up icon

Cons

  • Unable to calculate sustainability of dividends as Syngene International has not reported any payouts.
  • Unable to evaluate Syngene International's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Syngene International's dividend against the top 25% market benchmark as the company has not reported any payouts.
  • Syngene International's earnings are expected to grow by 1.5% yearly, however this is not considered high growth (20% yearly).
  • Syngene International's earnings growth is positive but not above the India market average.

Read More

Financials

Read More

Ratios

Read More

Shareholding

ShareholdersDEC 2025SEPT 2025JUN 2025MAR 2025DEC 2024
Promoters52.6852.6852.6852.7452.74
FII14.9616.3116.5019.4720.64
DII25.8424.6224.0521.5019.53
Public6.526.386.776.297.09
Government00000

Read More

Technical Analysis

RSI

34.59

MACD

-16.60

50 DMA

470.68

200 DMA

605.64

Support and Resistance

TypeR3R2R1PPS1S2S3
Classic640.78545.93484.07451.08389.22356.23261.38
Fibonacci545.93509.70487.32451.08414.85392.47356.23
Camarilla448.28439.59430.89451.08413.51404.81396.12

Pivots Level: Classic

R3

+189.70

640.78

R2

+94.85

545.93

R1

+32.98

484.07

451.08
451.08
Pivot Point
LTP: 397.85

S1

-61.87

389.22

S2

-94.85

356.23

S3

-189.70

261.38

Moving Average

SMAEMA

Period

Value

  • 10-EMA

    410.16

  • 20-EMA

    419.20

  • 30-EMA

    434.44

  • 50-EMA

    467.53

  • 100-EMA

    525.88

  • 200-EMA

    587.44

Read More

Corporate Actions

Announcement DatePurposeActionEx Date
22 Jan 2026board-meetingsQuarterly Results
05 Nov 2025board-meetingsQuarterly Results, Half Yearly Results
27 May 2025dividendFinal Dividend - Rs. - 1.2527 Jun 2025
23 Apr 2025dividend₹1.25 Dividend /Share27 Jun 2025
23 Apr 2025agm
28 May 2024dividendFinal Dividend - Rs. - 1.2528 Jun 2024
24 Apr 2024agm
24 Apr 2024dividend₹1.25 Dividend /Share28 Jun 2024
30 May 2023dividendFinal Dividend - Rs. - 0.530 Jun 2023
26 Apr 2023dividend₹0.50 Dividend /Share30 Jun 2023

Read More

Peer Comparison

Syngene International Ltd logo

Syngene International Ltd

Max Healthcare Institute Ltd logo

Max Healthcare Institute Ltd

Aster DM Healthcare Ltd logo

Aster DM Healthcare Ltd

Narayana Hrudayalaya Ltd logo

Narayana Hrudayalaya Ltd

Apollo Hospitals Enterprise Ltd logo

Apollo Hospitals Enterprise Ltd

Fortis Healthcare Ltd logo

Fortis Healthcare Ltd

Read More

Syngene International Ltd About

Syngene International is engaged in providing contract research and manufacturing services from lead generation to clinical supplies to pharmaceutical and biotechnology companies worldwide. Syngene’s services include integrated drug discovery and development capabilities in medicinal chemistry, biology, in vivo pharmacology, toxicology, custom synthesis, process R&D, cGMP manufacturing, formulation and analytical development along with Clinical development services.

Industry

Miscellaneous

Founded

1993

Headquarters

CEO

Kiran Mazumdar Shaw

Employees

Contact

Website icon

Website

http://www.syngeneintl.com

Email icon

Email

investor@syngeneintl.com; Mayank.Verma@syngeneintl

Phone icon

Phone

91-80-68915000/67758781

Location icon

Location

Biocon SEZ Biocon Park, Plot No 2 & 3 Bommasandra Inds, Bengaluru, Karnataka, 560099

Read More

Syngene International Ltd Company History

YearHistory
2020
  • Syngene ties up with HiMedia Laboratories to manufacture ELISA test kits for COVID-19.
  • Syngene joins global industry consortium to accelerate collaborative research in COVID-19 testing.
  • Syngene and PharmAust collaborate to manufacture GMP-grade Monepantel for Human Clinical Trials.
  • Bioprocessing Excellence Award 2020.
2021
  • Syngene receives India Pharma Awards 2021.
  • Syngene Ranked As One Of The Top 100 Indian Wealth Creators For 2021.
  • Syngene International extends long term research collaboration with Bristol Myers Squibb until 2030.
  • Syngene through Biocon Foundation partners with NIMHANS for BHUMI.
2022
  • Syngene International takes top honors at CMO Leadership Awards 2022 for contract manufacturing.
  • Syngene signs 10-year biologics manufacturing agreement with leading animal health company.
  • Syngene and the Research and Innovation Circle of Hyderabad (RICH) launch scholarship program for women studying STEM subjects.
2023
  • Winner of India's Best Managed Companies 2023 programme
  • Supply Chain Champion Award, 2023
  • Best Overall Sustainable Performance (Pharmaceutical) 2023
  • Biopharma Excellence Award (India Edition) 2023
  • Panbela announces issuance of new patent in Australia.
2024
  • Syngene received Pharmaceutical Technology Excellence Awards 2024.
  • Syngene received Asia Pacific Biologics CMO Excellence Awards 2024.
  • Syngene awarded CDMO Leadership Awards 2024.
  • Syngene secures silver rating in EcoVadis sustainability index, ranking in top 15% of assessed companies.
  • Syngene launches platform for rapid, enhanced protein production.
  • Syngene International named as one of India's Best Managed Companies by Deloitte India.

Read More

Deals

Client NameOrder SideQTYAvg PriceDate
BIOCON LIMITEDSell8000000857.6810 Dec 2024
BIOCON LIMITEDSell4000000056001 Feb 2023
GOVERNMENT OF SINGAPOREBuy1579920056001 Feb 2023
BIOCON LIMITEDSell4000000056002 Jan 2023
GOVERNMENT OF SINGAPOREBuy1579920056002 Jan 2023
ICICI PRUDENTIAL MUTUAL FUNDBuy282851056006 Sept 2022
BIOCON LIMITEDSell21789164560.0406 Sept 2022
BIOCON LIMITEDSell1556326612.116 May 2018
GAOLING FUND LPBuy150000051523 Nov 2017
STEADVIEW CAPITAL MAURITIUS LIMITEDSell1950000516.9223 Nov 2017

Read More

Syngene International Ltd News

Syngene Schedules Meeting with OrbiMed Advisors

Syngene International has scheduled a virtual one-to-one meeting with OrbiMed Advisors LLC on March 19, 2026, at 11:00 AM IST as per regulatory compliance requirements.

16 Mar 2026

companies

Syngene Gets Tax Penalty Relief for AY 2018-19

Syngene International receives order dropping penalty proceedings for Assessment Year 2018-19 after successful appeal resulted in Rs.2,78,45,669 expense relief.

14 Mar 2026

companies

Syngene Schedules Investor Meet with Alquity on Mar 18

Syngene International has scheduled a virtual one-to-one meeting with Alquity Investment Management on March 18, 2026, at 4:00 PM IST, with no UPSI disclosure planned.

13 Mar 2026

companies

Syngene International February Exports Drop 22% YoY

Syngene International reported exports of $6.6 million in February, marking a 22% decline from the previous year and a 32% drop from the preceding month, indicating challenging export conditions.

12 Mar 2026

co actions results

Syngene International announces senior management changes

Syngene International announces departure of three senior executives by April 30, 2026, and appointment of two new senior management personnel effective May 1, 2026, under regulatory disclosure requirements.

06 Mar 2026

stocks

Read More

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

pocketful logo

2022-25 Pocketful. All rights reserved, Built with in India

Version -5.76

app image 1app image 2

Stocks:

AllABCDEFGHIJKLMNOPQRSTUVWXYZ

Explore

Calculatorsfooter arrow down icon
Popular Calculatorsfooter arrow down icon
Group Stocksfooter arrow down icon

Others:

NSEBSECDSLNSDLSEBIMCXMSEINCDEXNSE IFSCINDIA INXAccount Closure FormDP Investor CharterBroker Investor Charter

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800